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Guest Editorial

Bio-monitoring the elimination of folic acid-preventable spina bifida and
anencephaly
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This is an invited editorial that praises the idea of serumlred cell folate monitoring of the elimination of
folic acid-preventable spina bifida.
O 2008 Elsevier Inc. All rights reserved.

Since 1991, we have had unequivocal evidence that folate deficiency is the primary cause of spina bifida and anencephaly (SBA)
in most of the world [1,2].Thus, if all women of reproductive age
consume enough folic acid, we can eliminate Folic Acid-Preventable
Spina Bifida and Anencephaly (FAP SBA) by primary prevention. It
is seldom that we have such an opportunity to prevent severe and
common birth defects. Unfortunately, we are far from accomplishing the elimination of these birth defects 131.
A key feature of the successful polio eradication campaign has
been timely monitoring of the progress or the lack of it and the
ability to determine when polio is eradicated in a country [4]. The
efforts to eliminate folic acid-preventable spina bifida and anencephaly also need a reliable. timely indicator to determine when
required folic acid fortification programs have been successfully
implemented and when a state or a country has prevented all or
almost all FAP SBA.
Pre- and post-fortification serum/plasma and/or red blood cell
folates have been measured in a variety of research designs-from
nationally representative surveys to convenience samples [5-81.
These data show that before folic acid fortification the mean
serumlplasma folate concentration is about 4nglml and rises
almost immediately to 8 or more nglml after the successful implementation of required folic acid fortification programs. Red cell
folate levels also rise after a period of several months 191. Thus,
the simple measurement of plasma or red cell folate can provide
the evidence needed to know if the fortification was successfully
implemented.
The implementation of a folic acid fortification program may
not provide enough folic acid to eliminate FAP SBA. If we knew
the serum/plasma or RBC folate concentration that would assure
the prevention of all FAP SBA. surveys of folate concentration in
women of reproductive age could determine whether or not all
had folate concentrations above this prevention cut-point. If all
women were above this cut-point. then we would ltnow that FAP
SBA was eliminated in that country. Likewise, if there were a significant proportion below this prevention cut-point, we would ltnow
that there was work to be done in the country to increase folic
acid consumption to a level sufficient to get all women above the
prevention cut-point. There has yet to be a generally agreed upon
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serum/plasma or RBC folate level that assures the elimination of
FAP SBA [lo]. In the absence of such a consensus, Bar-Oz and his
colleagues in a paper in this issue assume that elimination or near
elimination would occur when all women have a RBC folate of at
least 900 nmol/L. Given the available evidence, their assumption
is a reasonable one, albeit one that might go up or down with
new data. They show that. before fortification, almost no women
in Ontario had RBC folate levels above 900 nmol/L. After fortification. 40% remained below this cut point and were assumed to be
at unnecessary risk. These and other data show that folic acid fortification of flour in Canada has been highly effective in raising RBC
folateconcentrations and there has been a substantial prevention of
FAP SBA [7.11.12].It is likely that, if the concentration of folic acid in
flour doubled in Canada, most women would have RBC folate concentrations above 900nmol/L and most, if not all, FAP SBA would
be prevented.
As important as their paper is in assessing current prevention
in Ontario, it is more important that they have applied a biomarker
approach to monitor the progress towards the elimination of FAP
SBA. Their approach should be considered the current best way to
determine the proportion of women at unnecessary risk for FAP
SBA. It is likely that their method can be improved. We need to
build consensus and perform studies that will validate the most
appropriate epidemiological and laboratory methods to assess the
progress towards the elimination of FAP SBA in every country. A
serum/plasma and/or RBC folate survey would likely be a more
timely and less expensive approach to evaluate prevention than
would surveys of pregnancies affected with SBA. Since blood folates
rise after fortification, within a year of the implementation of fortification programs, one can estimate the proportion of women still
at risk of having pregnancies with FAP SBA. It would take several
years for enough babies to be born with spina bifida and anencephaly, for the data to be collected and analyzed. and for policy
recommendations to be made about needed changes in the fortification program. A folate bio-monitoring program would be less
expensive and could provide key data for policy within a year of
fortification.
Currently no group is funded to design and implement a folate
bio-monitoring program. For polio eradication. the CDC has had
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substantial and sustained funding to provide leadership and technical assistance to the polio eradication effort. Appropriations by
Congress,
$200
a year*have been
to the success of this program. Given the success that CDC has had
in prevention, it would seem reasonable for Congress also to provide CDC with sufficient,sustained resources to provide leadership
and technical assistance to accelerate the elimination of FAP SBA
around the world. Alternatively, foundations, other governments
or industries could provide the support for such a center.
This global technical assistance center and network should provide any country the epidemiological and laboratory support to
monitor the progress towards the elimination of FAPSBA.There will
be many activities and projects for this center. Initially the center
should:
1. Help countries to conduct surveys of serum/plasma or RBC folate
to determine whether or not mandatory folic acid fortification
programs have been successfully implemented.
2. Establish a task force to prepare and distribute a manual on how
to monitor progress towards the elimination of FAP SBA.
3. Advocate for and use new research that will improve our ability
to determine progress towards elimination in an accurately and
timely manner.
Work to achieve mandatory folic acid fortification should not
wait for the establishment of this center or its products. The
mandatory folic acid fortification programs in North America and
in Chile have been highly successful in preventing birth defects,
even though no country is known to have eliminated them. There
remains an urgent need for countries that have yet to require fortification to implement such programs now. Failure to do so means
that thousands of children will be born each year with preventable
spina bifida and anencephaly and that millions of people will have
unnecessary folate deficiency anemia. Readers of this journal are in
a unique position to advocate for the urgent elimination of FAP SBA.
We hope that as many as possible will work to provide the political
will to prevent these birth defects.

Disclosure
Godfrey Oakley is a co-inventor on a CDC-Johnson and Johlison
patent that would cover adding folic acid to contraceptive pills. He
has consulted for Johnson and Johnson on this issue.
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